Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

PURPOSE: We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor. METHODS: Patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Principais autores: Chesney, Jason, Puzanov, Igor, Collichio, Frances, Singh, Parminder, Milhem, Mohammed M., Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore F., Hauschild, Axel, Lebbé, Celeste, Chen, Lisa, Kim, Jenny J., Gansert, Jennifer, Andtbacka, Robert H.I., Kaufman, Howard L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
Rapid Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075852/
https://ncbi.nlm.nih.gov/pubmed/28981385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.7379
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados